With significant expertise in commercial and corporate law, Giulia has a well-balanced perspective on the life sciences and healthcare sector, thanks to considerable experience on both the legal and commercial issues of the pharmaceutical industry.
Throughout a well-rounded career, she has gained expertise in various legal fields, including civil and administrative litigation, with particular reference to pharmaceutical law which has been the focus of her practice for some years.
Playing a key role in Osborne Clarke’s life sciences and healthcare team, Giulia provides advisory services on regulatory issues, including the production and sale of pharmaceutical products, active product ingredients, medical devices as well as food supplements. She is also well versed in drafting contracts relating to clinical trials, market access, and supply and distribution.
Giulia has also spent some time seconded to an in-house role within a multinational company, giving her invaluable practical insight into the internal dynamics of large organisations and meaning she takes a business-oriented approach to her work.
Alongside her life sciences and healthcare specialism, Giulia has extensive experience in drafting commercial agreements, including real estate contracts, and has assisted Italian and foreign clients (including multinationals, and leaders in the pharmaceutical, dental and cinema industries) providing ongoing advice on ordinary and extraordinary corporate transactions, including M&A and the complex restructuring of corporate groups.
She is authorised to appear before the Italian Supreme Courts.
- Regulatory and compliance
- Real estate
- Dispute resolution
- Banking and finance
- Competition, antitrust and trade
Telemedicine in Italy takes next step following pandemic regulatory advance
Payback for medical devices: is litigation on the horizon in Italy?
The transfer of Data of non-profit clinical trials to pharmaceutical companies is now allowed in Italy
Compassionate Use in Europe
Is Italy's new law on rare diseases a starting or end point?
Medical device advertising in Italy: is authorisation by the Ministry of Health still required?
2022 Finance Act increases State investment in Italian national health system
Global healthcare's embrace of patient support programmes spurs regulatory action
Telemedicine on the rise in Europe
The European telemedicine industry is on the rise as a result of recent legalisation of activities such as remote treatment...
Article 17 of the 'Cura Italia' Decree: semplification of clinical trials for COVID-19 patients
Article 17 of law decree no. 18, dated 17 March 2020, published on even date in the extraordinary edition of...